Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

TOKYO--(BUSINESS WIRE)--Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and ADC for Patients with Previously Treated HER2+ Metastatic Solid Tumors